

vi: 31 January 2025

Review Article

# Gestational Inflammation: Its Foetal Control and the Proper Therapeutic Approach

Peer-approved: 31 January 2025

© The Author(s) 2024. This is an Open Access article under the CC BY 4.0 license.

Qeios, Vol. 7 (2025)  
ISSN: 2632-3834

Fortunato Vesce<sup>1</sup>

1. University of Ferrara, Italy

**Inflammation triggers coagulation. Gestational Inflammation with its vascular implications is the cause of the major obstetric complications, from sporadic and recurrent miscarriage, to foetal growth restriction, premature delivery with all its nefarious perinatal sequels, up to the most dramatic scenarios of foetal and maternal death: it is neither adequately diagnosed nor promptly and exhaustively counteracted by current obstetrics.**

**Controlling gestational inflammation in normal pregnancy is primarily a foetus's job. The vast majority of aneuploid foetuses are unable to control normal gestational inflammation, and are therefore spontaneously aborted. Euploid foetuses may be unable to control normal gestational inflammation, and in this case they are aborted, or suffer from the inflammatory complications of advanced pregnancy.**

**This article reports a selection of the best scientific evidence on gestational inflammation. It also analyses the current therapeutic approach, with particular regard to the use of glucocorticoids throughout pregnancy.**

## Premise

It is worth to consider in advance that pregnancy is made possible thanks to an invasion of maternal endometrium by the trophoblast surrounding the blastocyst. Such invasion generates a cellular reaction<sup>[1]</sup>, the nature of which is primarily of an inflammatory type. It belongs to the cellular branch of the immune response, leaving perfectly operative the humoral one.

A favorable outcome is only possible if the trophoblast is able to turn off the inflammatory endometrial reaction it itself has caused. This means that the physiological pregnancy is largely under foetal control. Foetuses (i.e. trophoblast) unable to properly modulate the local maternal reaction sign their own death warrant.

## The physiological role of the 'inflammatory mediators'

The normal evolution of pregnancy is the result of deep vascular changes in the maternal organism under the control of foetal mediators. According to their prevalent action, a taxonomic classification can divide these mediators into inflammatory and anti-inflammatory. However, they are known to play either role, depending on the cell type and the circumstances of their involvement, in response to the activation of the actors of the opposite function. Indeed, the so-called 'inflammatory' ones primarily regulate physiological functions, such as ovulation, menstruation, labor and many others. In search of scientific evidences of the physiologic role of such mediators, the receptor ligands for the inflammatory peptide N-formyl-methionyl-leucyl-phenylalanine (fMLP) were found to be present in amniotic fluid. Their concentration increases with labor, while fMLP

receptors are expressed in amnion tissue<sup>[2][3][4][5]</sup>. So, what are these inflammatory mediators for? Can normal labor be considered an inflammatory process? Not entirely. Certainly, it often presents with pain, heat, functional impairment, like it may happen during menstruation: and to some extent labor can be considered a delayed menstruation, as Gustavii pointed out a long time ago<sup>[6]</sup>.

Is fMLP involved in the control of menstruation as well? After all, understanding the physiological role of these mediators is not a simple matter of measurement. fMLP is only one among many chemotactic factors able to modulate cytokines, including IL-1 alpha and IL-1 beta gene expression and IL-6 secretion, which in turn are known to modulate inflammation<sup>[7]</sup>.

Therefore, it should be interesting to explore the behavior of the peptide in the genesis of premature labor and foetal systemic inflammation, a syndrome preceded by an increase of IL6 concentration in the foetal compartment. However, even if that were the case, it would be a drop in the ocean! A large network of gestational cytokines, chemokines, peptides and prostanoids have been investigated in both experimental and clinical conditions, with sometimes controversial results. Nevertheless, over the course of half a century, the inflammatory nature of the major complications of pregnancy has been widely recognized at least on a pathological level, if not on a clinical one.

In this article the concept of gestational inflammation will be discussed in its broadest sense, from the natural maternal immune response, to its physiological control by the foetus, up to its harmful pathological deviations. Furthermore, the therapeutic approach will be analyzed with particular attention to the balance of the mediators that trigger inflammation, thus paving the way for infection, and to the use of glucocorticoids for the prevention of pregnancy loss.

## **A look at the nature and mechanism of gestational inflammation**

Between the two endpoints of conception and delivery, the process of placentation takes place, during which the maternal and foetal immune systems interact with each other. This occurs through the release of specific mediators of opposite function, the maternal ones being more addressed towards

inflammation, whereas the foetal ones act against it. The earliest stage of the foetal-maternal competition occurs at the beginning of blastocyst implantation in the uterine mucosa. Mainstream clinicians are customarily considering such an early stage separately from advanced pregnancy, when the foetus is now capable of extrauterine life. Nevertheless, both from a biological and clinical point of view, the functional evolution of the trophoblast must be considered a unitary and continuous process until delivery. Indeed, the same inflammatory deviation of its function that triggers miscarriage, later can lead to premature birth, chorioamnionitis, nefarious perinatal complications, up to the loss of both the foetus and the mother.

During the three-days travel from the tube to the uterine cavity the product of conception does not need to come into contact with the maternal blood, since everything he needs is already in his baggage. Later, when the trophoblast cells reach the mucosa, they differentiate into two types, respectively called extra-villous and villous. The first type is responsible for structural and functional changes in the maternal vessels<sup>[5]</sup>. It penetrates the uterine arterioles and disrupts their wall, causing the leakage of blood in which the chorionic villi are immersed to drain increasing quantities of nutrients and oxygen.

As in any other vascular district of the body, this generates an inflammatory reaction, aimed at reducing blood leakage by means of vasoconstriction and coagulation. The activation of such a natural response would appear to hinder the ultimate goal of a normal birth, but in physiological pregnancy this is not the case. In fact, the foetal immune system takes over the maternal one, to preserve optimal placental perfusion until childbirth. In its competition with the maternal immune system, foetal self-defense is essentially accomplished by counteracting vasoconstriction and blood coagulation. For this purpose extravillous trophoblast cells progressively eliminate the smooth muscle from the wall of the spiral artery up to its myometrial tract. The consequent vasodilatory effect produces a continuous, low-resistance blood flow. At the same time coagulation is prevented by replacing the endothelial lining of the vascular intima with trophoblastic cells. In this way, the local maternal platelet activation does not take place, and the thrombosis is not triggered.

These structural changes of the uterine arterioles were clearly described by Harold Fox in his classic text entitled 'Pathology of the Placenta'<sup>[8]</sup>.

At the same time the trophoblastic cells directly produce functional mediators<sup>[5]</sup>, and stimulate the release of many others by maternal platelets, as well as by immune and other cells. Therefore it is right to state that pregnancy is directly under the control of the foetus itself: *foetus faber fortunae suae!*

On the other hand, contrary to some unproven opinions, the maternal immunity against infectious diseases remains fully operative throughout pregnancy. The idea of an assumptive “fragility” of the pregnant woman is completely devoid of any scientific basis. It derives solely from the hypothesis that the foetus should be ‘rejected’, because the mother’s immune system does not recognize its paternal genetic component. According to this opinion, maternal tolerance would be accomplished through a reduction of the humoral immunity, thus leading to an increased risk of infection. A corollary of this unproven risk should be the need to resort to vaccines, whose number is continuously increasing, and whose efficacy and safety have never been reliably investigated. Instead, contrary to the opinion of an increased risk of serious infections accredited by World Health Organization, the admission rate to Intensive Care Unit is significantly lower for pregnant women. Moreover, no increased need for ventilatory support, nor a greater likelihood of severe outcomes and maternal death compared to either the general population or non-pregnant women of reproductive age is reported. Only a higher rate of hospitalization is registered, rightly ascribed to a better care for motherhood<sup>[9]</sup>.

Surprisingly, however, the above data have been interpreted in the opposite meaning by others<sup>[10]</sup>. To give a greater credence to an increased risk of maternal death, these Authors go back to the 1918 flu pandemic, an era when the therapeutic efficacy of antibiotics, anticoagulants and anti-inflammatory drugs was unknown!

Unfortunately, however, vaccination, by definition entails inflammation, thus strengthening the normal maternal cellular immune reaction<sup>[11]</sup>, with a consequent increased risk of foetal demise. It is the author’s opinion that, given the current uncertainties, it may be best to exercise caution regarding vaccinations during pregnancy until more research is available.

## Foetal-maternal regulation of immune and vascular function

Many of the pregnancy-related mediators of the cellular functions are secreted by two subpopulations of lymphocytes (Th1 and Th2) derived from the functionally undiscriminated type (Th0). Th1-type produces mainly interleukins (IL-1, IL-2, IL-12, IL-15, IL-18), interferon gamma (IFN- $\gamma$ ) and tumor necrosis factor-alpha (TNF- $\alpha$ ), known to mediate cellular immunity. Th2 produces IL-4, IL-5, IL-6, IL-10, IL-13 and granulocyte-macrophage colony stimulating factor (GM-CSF), which control the humoral response<sup>[12][13]</sup>. Moreover, Th2 cytokines prevent Th1 cytokine secretion<sup>[14]</sup>.

The pro-inflammatory/anti-inflammatory cytokine ratio, is enhanced in preeclampsia. It is probably associated to an excessive production of inflammatory agents, among which IL-12<sup>[15]</sup>. Placental ischemia, consequent to poor spiral artery remodeling<sup>[16]</sup>, enhanced Th1/Th2 ratio<sup>[17]</sup> and pro-angiogenic/anti-angiogenic factor imbalance<sup>[18]</sup> may promote inflammatory changes through the release of Th-1 cytokines and ROS with consequent endothelial dysfunction, leading to the release of humoral factors responsible for the clinical symptoms of preeclampsia<sup>[19]</sup>.

As for the gestational evolution of cytokine balance, based on circulating levels of interferon-gamma (IFN-gamma) and interleukin-6 (IL-6) as Th1 and Th2 biomarkers respectively, the variation of their ratio was investigated in the maternal blood of 35 women from 10 to 40 weeks of pregnancy. It is important to note that IFN-gamma levels decrease with gestational age, whereas those of IL-6 increase. The IFN-gamma/IL-6 ratio switches around the 19th week of pregnancy. Therefore the Authors suggest that the Th1 bias may be prevailing at the beginning of pregnancy, balanced in the middle and supplanted by the Th2 bias at the end<sup>[20]</sup>.

These results should be taken into account when the cytokines are tested for statistical or diagnostic purposes.

Many other factors are involved in the differentiation and specialization of trophoblastic cells from implantation to delivery. During early pregnancy, low oxygen is reported to prevent trophoblast differentiation towards an invasive phenotype. Low oxygen effects are mediated by hypoxia inducible factor-1 (HIF-1 $\alpha$  subunit), whose expression

parallels that of transforming growth factor- $\beta$ 3 (TGF $\beta$ 3), an inhibitor of early trophoblast differentiation<sup>[21][22]</sup>.

Abnormalities in TGF- $\beta$ 3 expression are associated with preeclampsia and it has been demonstrated that down-regulation of this growth factor restores the invasive capability of preeclamptic trophoblast cells<sup>[23]</sup>.

A crucial role for optimal foetal oxygenation and growth is exerted by prostacyclin (PGI<sub>2</sub>), a prostanoid with vasodilatory and anticoagulant function. It is produced by both the mother and the foetus for the entire duration of pregnancy. Placental cells in culture synthesize and release PGI<sub>2</sub>. Its production appears to increase with gestational age, so that preterm and term placental PGI<sub>2</sub> production is significantly greater than that in first-trimester.

Notably, synthesis of PGI<sub>2</sub> is inhibited by the cyclo-oxygenase inhibitors indomethacin and aspirin, a potentially dangerous effect, considering the wide clinical use of these drugs<sup>[24]</sup>.

Indeed, as patients with recurrent miscarriage have significantly increased platelet aggregation in response to arachidonic acid, the use of aspirin in the management of this condition is suggested<sup>[25]</sup>. Therefore, aspirin is expected to hinder thromboxane on the one hand, thus counteracting the formation of the platelet thrombus, but also to inhibit prostacyclin production on the other, in this way promoting vasoconstriction and thrombosis. Indeed, the action of prostacyclin is normally counterbalanced by thromboxane (TxA<sub>2</sub>), a prostanoid responsible for vasoconstriction and thrombosis, which is released by various cells, among which endothelial, macrophages and neutrophils. The enhancement of thromboxane release is the natural consequence of inflammation. The maternal inflammatory response is not limited to platelet activation, but widely affects other tissues, among which the endothelial lining of uterine arteries. Women whose pregnancies end in abortion have higher output of 2,3-dinor-TxB<sub>2</sub> (a thromboxane metabolite) and lower excretion of 2,3-dinor-6-keto-PGF<sub>1 $\alpha$</sub>  (a prostacyclin metabolite), with a lower ratio of prostacyclin to thromboxane, indicating a thromboxane dominance and prostacyclin deficiency compared with women whose pregnancies proceed to term<sup>[26]</sup>.

These data underline the importance of a balanced prostacyclin/thromboxane ratio in pregnancy.

In apparent contrast with the evidences that increased platelet aggregation is a cause of severe complications, among which increased miscarriage rate, pre-eclampsia and pregnancy loss, reduced platelet aggregation in response to adenosine diphosphate, and thrombin receptor activating peptide was reported in patients with history of recurrent miscarriage in comparison with those of the same group who subsequently have successful pregnancies. Women with subsequent miscarriages also have a trend towards reduced platelet aggregation in response to epinephrine<sup>[27]</sup>.

However, it must be considered that in vivo platelets dysfunction is a complex process than cannot be simply reduced to more or less experimental in vitro aggregation.

Further questions regarding platelet dysfunction concern the complexity of the maternal inflammatory response and the adequacy of the adopted therapy. As it will be seen later, the ability of aspirin to inhibit thromboxane formation in vitro does not provide any significant clinical advantage in terms of live birth rate and foetal well-being.

## Potential causes of enhanced gestational inflammation

Once the prevalent inflammatory nature of major obstetric complications is understood, its prevailing causes must be carefully considered. In this regard, the current attitude is to look for maternal infectious, immune and genetic causes.

As for the first, the stubborn search for potential pathogens appears to be no longer necessary, since the foetus inability to turn off the maternal immune reaction - unleashed by himself - is sufficient to explain even the most serious consequences. After all, free mother-to-child transmission of viruses and their specific antibodies has been reported in normal pregnancy<sup>[28][29]</sup>. Moreover, HPV infection is rare in chorionic villi, and is not related to abortion<sup>[30]</sup>. As for *Ureaplasma parvum* and *urealyticum*, *Mycoplasma genitalium* and *hominis* and *Chlamydia trachomatis*, their DNA sequences are found with similar frequency in peripheral blood mononuclear cells of spontaneous and voluntary aborters<sup>[31]</sup>. On the other hand, it is logical to believe that the mere presence of viruses and bacteria is not a sufficient cause of disease, because it is known that healthy carriers do exist. The independence of the onset of inflammation from pathogens is indirectly demonstrated in the above

mentioned 'syndrome of the systemic foetal inflammatory response' (Romero – Gomez Syndrome)<sup>[32]</sup>. In this condition high levels of foetal IL6 are found in the foetal compartment before the onset of premature birth symptoms, suggesting the existence of foetal cytokine imbalance preceding the eventual infection. Nevertheless, the widely held belief that inflammation is triggered by infection is claimed on the basis of the curative effect of antibiotics. However it has been shown that, in the absence of infection, Ampicillin is able to inhibit amniotic Prostaglandin E and IL6 release, in this way directly counteracting inflammation<sup>[33][34]</sup>.

Furthermore it is reported that Ceftriaxone and Gentamicin exert the same action although to a lesser extent. On the contrary, Tetracycline and Erythromycin do not influence the prostanoïd output. The inhibitory (i.e. anti-inflammatory) effect of Ampicillin is potentiated in an additive manner by Ceftriaxone, reduced by Gentamycin and eliminated by Tetracycline and Erythromycin<sup>[35]</sup>.

These data should open a serious debate on the current interpretation of healing from antibiotics: is it the result of their direct anti-inflammatory action rather than the anti-bacterial one? Or: in what extent it is the result of both?

Autoimmune syndromes and diseases of the maternal connective tissue are a well known cause of recurrent miscarriage. Nevertheless, successful pregnancy is possible, although at the cost of an increased risk of complications<sup>[36]</sup>.

## The foetal-maternal genetic control of gestational inflammation

A large number of maternal and foetal cells produce immune mediators, but a clear assessment of their role in the genesis of different gestational situations has not been yet sufficiently clarified. While the role of the maternal immune system is beyond question, its control by the foetus still awaits to be adequately understood. Indeed, there is much evidence to suggest that the foetus itself governs the balance of gestational immunity. The above mentioned Romero–Gomez Syndrome, for example, indicates that the foetal inflammatory state may not be triggered by infection. Accordingly, it has been also postulated that successful pregnancy induces an immune bias towards Th2 immunity, and a Th2 cytokines

imbalance is believed to cause intrauterine growth restriction and foetal death. Further evidence points to a foetal role in triggering increased or unbalanced release of pro-inflammatory mediators. Indeed, maternal peripheral mononuclear cells stimulated with trophoblast antigens from growth restricted fetuses produce higher levels of pro-inflammatory cytokines compared with normally grown fetuses<sup>[37][38][39]</sup>.

Growth restriction, therefore, can be considered a consequence of low utero-placental perfusion caused by vasoconstriction and thrombosis of uterine spiral arterioles, i.e. by the normal maternal inflammatory response, which growth-restricted fetuses lack the ability to switch off. This foetal idiopathic inability may well be one cause of the shift towards Th1-type immunity<sup>[39]</sup> which is a reported cause of 'unexplained' pregnancy failure.

Once the foetus' inability to properly control the maternal inflammatory reaction has been recognized, we must find out where it originates from. To answer this question the mediators of inflammation, coagulation and vascular function released by aneuploid fetuses was investigated, in order to verify whether an increased or unbalanced output could justify their high abortion rate.

A raised amniotic fluid level of endothelin, a potent vasoconstrictor, was found in the presence of aneuploidy compared to normal pregnancies<sup>[40]</sup>. Moreover, abnormality of the plasminogen activation system was reported in aneuploid pregnancies, possibly leading to impaired utero-placental perfusion, thus to abortion, foetal growth restriction and death<sup>[41]</sup>. Accordingly, amniotic fluid of Down Syndrome pregnancies display increased TGF- $\beta$  activity and lacked IL-2 immunoactivity<sup>[42]</sup>. Moreover, down-regulation of adhesion molecules such as integrin- $\alpha$ , and upregulation of MMP-9 are reported in trisomy 21, with possible impairment in trophoblast function. These alterations may be responsible for the increase in cytotrophoblast apoptosis<sup>[43]</sup>. Further amniotic fluid abnormalities in aneuploid pregnancies are an increase of interleukin-6 ( $P = 0.034$ ) and a decrease of interleukin-8 ( $P < 0.0001$ )<sup>[44]</sup>.

In addition, the receptors of adenosine, a pro-angiogenic nucleoside, were investigated in 71 first trimester chorionic villi samples and cultured mesenchymal cells from euploid and trisomy 21 pregnancies. Overall, the adenosine transduction

cascade appears to be disturbed in Trisomy 21 through reduced expression of A<sub>2</sub>B and A<sub>1</sub>A receptors<sup>[45]</sup>.

All these anomalies of mediators of inflammation, coagulation and vascular function are a cause of foetal growth restriction, malformation and death, thus leading to the high rate of aneuploid pregnancy loss.

If the above reported evidences speak in favor of a foetal genetic cause for the lack of a proper control of immune and vascular function in the presence of aneuploidy, what can be said for euploidy?

Progress in genetic polymorphisms research answers this question. Genetic polymorphism means that the structure or nucleotide arrangement of the same gene may vary between individuals. The variations are compatible with life, and may affect numerous genes, including those associated with angiogenesis, thrombogenesis and immune response<sup>[46]</sup>.

Maternal common inflammatory polymorphisms entail an increased risk of recurrent miscarriage and preterm birth<sup>[47][48]</sup>. Consistent with the increased risk of preterm birth that inflammatory polymorphisms entail, a decreased risk is reported for the anti-inflammatory ones<sup>[49]</sup>.

Furthermore, maternal polymorphisms of the immunoregulatory genes IL10, MBL2, TNFRSF6 and TGFB1 influence the susceptibility to chorioamnionitis and other unfavorable pregnancy outcomes<sup>[50]</sup>.

While maternal polymorphisms are widely studied, the same cannot be said for the foetal ones. This reflects the current and often erroneous opinion that adverse pregnancy events are attributable to maternal pathological conditions. On the contrary, since both the maternal and foetal immune systems modulate the utero-placental function, foetal genetic polymorphisms have the same importance as maternal ones in determining the fate of the pregnancy.

## Clinical implications of the foetal-maternal immune system mutual modulation

The evidence reported above is only a small part of the large amount of data in the scientific literature on cytokine modulation in pregnancy. As mentioned in the introduction, the maternal inflammatory response is not in itself a pathological event, as far as the foetus is able to counteract it. It turns into pathology only when the spatial-temporal production of inflammatory cytokines is uncontrolled, and the Th1

foetal-maternal immune response takes over the Th2 one<sup>[51]</sup>.

So, slowly, the idea of counteracting inflammation has made its way into the minds of obstetricians. It must be said however that the maternal immune reaction to trophoblast invasion is not currently seen as a possible cause of miscarriage. According to mainstream obstetrics, the most accredited causes are maternal diseases, including connective tissue chronic inflammation, thrombophilia and infection. Indeed, an increased risk of miscarriage and other complications are registered in the presence of such pathologic conditions. Nevertheless, physiological pregnancy, albeit less frequently, can occur in these patients, thus confirming the opinion that a better genetic polymorphism of the new foetus may be able to control the maternal immune system.

Ignoring the possible role of gestational inflammation in the genesis of obstetrical complications, current obstetrics does not effectively counteract it. Therapy is still basically anchored to weak measures dating back to the first half of the last century: robust doses of progesterone, weak doses of aspirin and in some cases ineffective glucocorticoids.

### Progesterone

Progestagens are prescribed routinely for the protection of early and late pregnancy. Initially the reason for their use was the maintenance of electrical and mechanical quiescence of the myometrium. As for their utility, the need of progesterone action on the endometrium for implantation is known and beyond question. It is worthwhile to recall that around the end of last century a combination hydroxiprogesterone caproate plus estradiol valerate was approved for cure of threatened miscarriage<sup>[52]</sup> as well as for osteopenia due to hypogonadism<sup>[53][54]</sup>, for stimulation of breast enlargement<sup>[55]</sup> and also for contraception<sup>[56]</sup>! However, so far there is no clinical evidence of real efficacy in protecting pregnancy against severe inflammatory complications. Only in 2007 the estrogen-progestin combination was withdrawn from the Italian market. Nevertheless, new potential indications to progesterone administration are produced by the tireless scientific research, among which a possible anti-inflammatory action that should make its use suitable against miscarriage<sup>[57]</sup>. Fortunately, however, the real usefulness of progestogens in the prevention of obstetric complications is slowly coming out. According to FIGO Good Practice Recommendations<sup>[58]</sup>, evidence on the

use of progesterone for prevention of recurrent miscarriage demonstrates no significant difference in live birth rates compared to placebo. Similarly, a recent meta-analysis on seven randomised trials involving 5,682 women, concluded that progestogens probably make little or no difference to live birth rate for women with threatened or recurrent miscarriage<sup>[59]</sup>. Furthermore, the method of pessary administration of 400 mg vaginal progesterone for threatened miscarriage does not increase live birth-rate<sup>[60]</sup>. Although other Authors seem to interpret the recommendations of the guidelines in a more reassuring way<sup>[61]</sup>, a further meta-analysis confirmed that progestogens probably make little or no difference to live birth rate for women with threatened or recurrent miscarriage<sup>[62]</sup>.

It should seem instead that Vaginal micronized progesterone, may increase the live birth rate for women with a history of one or more previous miscarriages and early pregnancy bleeding: thus progesterone shows inconsistent behavior in relation to the administration route. However, as regards the efficacy limited to cases with early bleeding, one possible explanation could be that some of them may not be true cases of threatened abortion: the blood may come from the decidua parietalis. Indeed, it is known that in early pregnancy the gestational sac does not occupy the entire uterine cavity, and there are women that may experience mild bleeding during the period of missed menstruation until late in the second trimester: this has little or nothing to do with threatened miscarriage. Strictly speaking, bleeding should be considered a sign of threatened abortion only when it is caused by the disruption of the normal relationship between chorionic villi and uterine spiral arterioles. In a previous randomized multicenter trial in which 400 mg vaginal progesterone was given twice daily to patients with history of recurrent miscarriage from a positive pregnancy test until 12 weeks, there was no significant difference for live birth after 24 weeks compared to placebo<sup>[63]</sup>. Nevertheless, the National Institute for Health and Care Excellence (NICE) recommend to offer vaginal micronised progesterone 400 mg twice daily until 16 completed weeks to pregnant women with vaginal bleeding and history of one previous miscarriage. Actually, a single miscarriage can be due to causes that do not benefit from progesterone, such as occasional aneuploidy. Moreover, the duration of the therapy is questioned. It has been highlighted that the increase in live birth rate at 34 weeks is only 3%; it is registered only in women with 3 previous

miscarriages, and the beneficial effect occurs at 9 weeks gestation, i.e. at the time of the shift in progesterone production from the corpus luteum to the placenta. This suggests that there is no need of the hormone supplementation until the 16 week. The need to investigate the long term effects of progesterone on brain development has also been highlighted<sup>[64]</sup>.

The American College of Obstetrics and Gynecology Clinical Guidance for prevention of recurrent premature birth by progesterone supplementation was recently updated. Quoting Conde-Agudelo and Romero<sup>[65]</sup>, the Committee states that vaginal progesterone may be prescribed in women with history of preterm birth, singleton pregnancy and a shortened cervix. On the contrary, prevention of recurrent preterm birth between 20 and 37 weeks gestation with intramuscular administration of 17-OHP is not supported by the current body of evidence, and therefore it is not approved by the FDA<sup>[66]</sup>. At this regard, the American College Committee notes that the FDA decision does not appear to be based on “safety concerns”, and “does not provide any basis for evaluating potential progesterone efficacy in a subset of the general population”: in other words, it seems that the Committee wants to distance itself from the FDA’s position. However, the Committee, does not seem at all surprised by the difference in efficacy of progesterone, which appears to be mild via the vaginal route, but is completely absent via the systemic route. It is not easy to figure out the reason of the intramuscular route failure, considering the prompt hematogenous spread to all organs and tissues, including the vagina. Finally, one would expect that, by inhibiting myometrial contraction, progesterone administered before cervical shortening would be more effective than after the process has already begun. In addition, the concern of the American Committee for the apparent indifference of FDA as regards safety and potential efficacy on population subsets seems to be misplaced, because it may be relevant to research, but not yet to clinical care. How can these incongruity be explained? It would seem that proven clinical efficacy is still an essential condition for authorising the administration of a drug to the human population.

Further attempts to support the mild action of progesterone have been made by combining the therapy with cerclage. However, the hormone is supposed to counteract the increased myometrial contractility triggered by gestational inflammation, while the surgical tightening of the cervix can only be effective in the absence of inflammatory

myometrial contractions. Therefore, an eventually increased efficacy of this combined approach requires that patients with two different pathogenic mechanisms are mixed in the study population. Nevertheless, a trial speaks in favor of an increased efficacy of combined progesterone and cerclage in singleton gestation compared to each of the two single therapies<sup>[67][68]</sup>. On the contrary, a meta-analysis evaluating both the vaginal and intramuscular route of progesterone combined with cerclage and pessary in twin pregnancies with short cervical length reported no reduction of preterm birth < 34 weeks of gestation<sup>[69]</sup>.

Overall, the efficacy of progesterone in the management of miscarriage, premature birth, pregnancy loss and related complications appears to be uncertain or weak, and does not justify its widespread and indiscriminate prescription.

### *Aspirin*

The pathogenic link between inflammation and thrombosis, and their role in obstetric complications guided some clinical preventive strategies. As above mentioned, thromboxane A<sub>2</sub> is released from platelets, macrophages, neutrophils, trophoblast and endothelial cells, as a consequence of tissue injury and inflammation. In addition, it is also reported to augment cellular immune responses and inflammatory tissue injury<sup>[70]</sup>. Vasoconstriction and platelet aggregation caused by the prevalent action of thromboxane are attenuated by aspirin, whose inhibitory action is supposed not to extend to prostacyclin. Therefore, based on the known deficiency in prostacyclin and overproduction of thromboxane A<sub>2</sub> in women with history of recurrent miscarriage, 50 mg aspirin were daily given throughout pregnancy to 66 patients. The therapy was able to decrease thromboxane A<sub>2</sub> production without influence on prostacyclin concentration, but no improvement of live birth rate was observed<sup>[71]</sup>. Low dose aspirin was also recommended for prevention and cure of preeclampsia because the disease is characterized by an imbalance of the thromboxane/prostacyclin ratio, due to increased thromboxane production.

On the other hand, attempts to treat preeclampsia by direct prostacyclin administration yielded poor results<sup>[72]</sup>.

However, current evidence does not support low-dose aspirin for the prevention of miscarriage, fetal growth

restriction, stillbirth and preterm birth<sup>[73]</sup>.

As regards the mild effectiveness of aspirin, it must be considered that gestational inflammation cannot be reduced to the simple increase of thromboxane: it involves a series of mediators of cellular immunity that may be insensitive to the COX2 inhibitory action of aspirin: it is logical to assume that a higher degree of inflammation requires a stronger protection. It was therefore thought that this could somehow be obtained by combining aspirin with heparin.

### *Heparin*

Ten years ago a meta-analysis evaluated nine studies that included 1228 women with a history of recurrent miscarriage, with or without inherited thrombophilia, treated with aspirin and/or heparin: no beneficial effect of the anticoagulant in studies at low risk of bias was found<sup>[74]</sup>. Soon after, thromboprophylaxis with 4000 IU/day low molecular weight heparin was tested in a prospective observational study on 150 women with a history of two or more first trimester miscarriage. Contrary to the result of the previous meta-analysis, live birth was achieved 85%, compared to 66% in the untreated control group<sup>[75]</sup>. Moreover, an increase in live birth rate has been reported by combining aspirin plus heparin in women with persistent antiphospholipid antibodies<sup>[76]</sup>. On the contrary, in a more recent international open-label, randomised controlled trial, low molecular weight heparin administered to women who had two or more pregnancy losses and confirmed inherited thrombophilia did not result in higher livebirth rates<sup>[77]</sup>.

### *Glucocorticoids (GC)*

Cortisone was used, in 1953, to treat hyperemesis gravidarum. 29 women were given 25 to 75 mg/day doses for 5 to 64 days, with complete remission of the symptoms within 36 hours, without any negative effect on the neonates<sup>[78]</sup>. Today glucocorticoids prescription is widespread during the mid- and late pregnancy, while little is known about its potential significance in early pregnancy. Stimulation of HCG secretion, suppression of uterine Natural killer cells and promotion of trophoblast growth/invasion have been reported among the positive effects, while the negative could be inhibition of cytokine-prostaglandin signalling, restriction of trophoblast invasion following up-regulation of plasminogen



activation inhibitor-1, induction of apoptosis, and inhibition of embryonic and placental growth<sup>[79]</sup>.

The clinical rationale for the use of GC in the management of the major obstetrics complications is simple: since all of them have an inflammatory pathogenesis, all of them may benefit from the complex anti-inflammatory action of these hormones. It could be argued that the other drugs mentioned above also exert a direct or indirect anti-inflammatory action, but their effectiveness is very limited. GC instead are known to control the mediators of cellular functions, among which IL-1, IL-6, IL-8, Tumor necrosis factor, Granulocyte-macrophage Colony-stimulating factor and Monocyte chemotactic protein-1 factor<sup>[80]</sup>. Their action is exerted also on cellular cytokine receptors, which are increased in some cell types, decreased in others<sup>[81]</sup>. Other examples of the regulatory actions of GC are down-regulation of the expression of the cellular receptors that recognise a variety of pathogens, named Toll-like receptors<sup>[82]</sup> as well as suppression of pro-inflammatory and up-regulation of anti-inflammatory cytokines<sup>[83]</sup>. Moreover, betamethasone reverses the migration dysfunction induced by arginine-vasopressin in HTR8/Svneo trophoblastic cells by reverting the matrix metalloproteinase-9 associated inflammation. Therefore, since arginine-vasopressin secretion is elevated throughout gestation in pregnancies complicated by pre-eclampsia, the use of betamethasone has been suggested as a novel therapeutic strategy for this syndrome<sup>[84]</sup>. The above mentioned effects on cells, cytokines and receptors are indicative of the vast control that GC exert on body functions. Nevertheless, despite the logical and experimental premises of their anti-inflammatory effectiveness, they are rarely used in pregnancy with this specific purpose. Even when they clearly do exert it, the result of their application is interpreted differently. For example, the betamethasone life-saving prevention and cure of neonatal hyaline membrane disease of the lung, is currently all attributed to little-known maturational processes. Actually, the hormone directly stimulates lecithin release from the human foetal membranes with a greater amnion response<sup>[85]</sup>. This complex action, recently confirmed in the rabbit lung, appears to be mediated by a molecular mechanism that causes a decrease of Forkhead box M1, a protein involved in lung development<sup>[86]</sup>. However a large part of the ominous perinatal complication of premature

neonates that benefit from betamethasone, including respiratory distress, encephalopathy and necrotizing enterocolitis, is a direct consequence of inflammation rather than prematurity. Therefore, one should wonder to what extent the life-saving effect of betamethasone is attributable to the stimulated maturation as opposed to its powerful anti-inflammatory action.

Part of the caution in prescribing GC is due to the fear of adverse embryo-foetal malformative or maturation events, some of which have been produced experimentally in laboratory animals. As a consequence there is a widespread tendency to avoid prescribing in early pregnancy, or to resort to poorly effective types of these hormones. It is also believed that prednisolone does not reach the foetus, and therefore cannot cause adverse effects on it. This is a questionable belief, since steroids are fat-soluble, and therefore freely cross the cell membranes. Accordingly, placental 11 $\beta$ -HSD2 has been shown to metabolise beclomethasone, prednisolone, dexamethasone and betamethasone<sup>[87]</sup>. Despite the above mentioned prejudices, the use of GC, including fluorinated, is the mainstay for a variety of maternal and foetal pathologic conditions. Absolute indications are Addison syndrome and hypopituitarism. Furthermore, they are largely used in pregnant women with asthma, collagen disease, ulcerative colitis, regional enteritis, and those needing immunosuppression. The most frequent foetal indications to their use are reported below.

### *Foetal atrio-ventricular block*

Isolated foetal complete atrio-ventricular block (AVB) is a condition that occurs in 1 of every 20,000 pregnancies. It results from lupus erythematosus, due to transplacental passage of maternal anti-Ro/SSA and/or anti-La/SSB antibodies. However other rheumatic diseases, among which Sjogren syndrome may be involved, and even fetuses of asymptomatic women can be affected.

Complete AVB usually develops during gestational weeks 16 to 24, with a 15 to 30% foetal mortality rate, and two thirds of affected offspring requiring permanent pacing. The condition is associated with endocardial fibroelastosis and possible late-onset cardiomyopathy<sup>[88]</sup>, fluorinated Gc such as dexamethasone or betamethasone, given to the mother before 16 weeks' gestation, can prevent progression to third-degree AVB, alleviate cardiomyopathy<sup>[89]</sup>, and reduce the risk of developing

antibody-mediated congenital heart block in the offspring<sup>[90]</sup>. Moreover, by means of foetal kinetocardiogram it has been shown that fluorinated steroids normalize atrioventricular conduction in first-degree AVB<sup>[91]</sup>. However, not all the above effects are confirmed, although there is agreement on the decreased risk of subsequent cardiomyopathy<sup>[91]</sup>. Adverse effects on the foetal central nervous system, lung, retina, and adrenal glands have been ascribed to fluorinated corticosteroids administration. However, since they are associated with premature or very low-birth-weight newborns, the poor outcome can hardly be ascribed to GCs: rather it should be accepted that, without treatment, those fetuses would never survive. Moreover, neurodevelopmental problems appear to be associated with postnatal rather than antenatal dexamethasone therapy. To avoid fluorinated steroids in women who previously had children with AVB or skin rash, intravenous immunoglobulin is suggested. In these patients, serial echocardiograms are needed to detect premature atrial contractions or moderate pericardial effusion, that might be a target of preventive steroidal therapy<sup>[92]</sup>. It is believed that in the presence of alarming symptoms, betamethasone is safer than dexamethasone<sup>[93]</sup>.

A recent study evaluated long-term outcomes after antenatal betamethasone therapy for AVB prevention. Body weight and height of the fourteen children enrolled were within normal range, all had normal intelligence, and none had autism<sup>[94]</sup>.

### *Congenital Adrenal Hyperplasia*

Congenital Adrenal Hyperplasia is caused by the loss or decreased activity of the enzymes involved in cortisol biosynthesis. In the vast majority of cases 21-hydroxylase deficiency is found due to mutations in the gene CYP21A2, located in the short arm of chromosome 6<sup>[95][96]</sup>. Congenital adrenal hyperplasia is a cause of physical and psychological virilization in affected females. Prenatal diagnosis is needed in pregnancies at risk, followed by GC administration in the positive cases. Chorionic villus sampling has been preferred because it can be performed at the 10th-12th week of gestation, much earlier than amniocentesis. A significant improvement is represented today by the noninvasive diagnosis using cell-free DNA in maternal plasma<sup>[97]</sup>.

Dexamethasone administration to the pregnant mother is effective in reducing genital virilization.

Data from large human studies show that dexamethasone administered even before 10 weeks of gestation does not induce significant or enduring side effects neither in the mother nor in the foetus, and the newborns do not differ in weight, length, or head circumference from untreated unaffected newborns<sup>[98]</sup>.

### *Cystic adenomatoid malformation of the lung*

Cystic adenomatoid malformations of the foetal lung (CCAM) are rare embryonic developmental abnormalities characterized by overgrowth of the terminal respiratory bronchioles at the expense of the saccular spaces. Although rare cases of spontaneous resolution are reported, CCAM are generally coupled with high incidence of foetal or neonatal death. Several cases are reported about the efficacy of betamethasone in the management of CCAM complicated by fetal hydrops. The standard dose of 12 mg, twice 24 hours apart, for prevention of hyaline membrane disease lead to the complete resolution of the condition. In a clinical study on eleven patients survival was 100% in fetuses with hydrops or a CCAM, and resolution of hydrops was seen in 80% of steroid-treated patients<sup>[99]</sup>. In some cases, however, despite the therapy and the resolution of hydrops, late intrauterine death occurred, suggesting that the malformation may have a preeminent role in the final outcome<sup>[100]</sup>. While negative clinical effects of betamethasone are not reported in these patients, it seems that the clinical assessment this pathologic condition requires a deeper clinical assessment<sup>[101]</sup>.

### *Alloimmune Thrombocytopenia*

Alloimmune thrombocytopenia is analogous to the foetal/neonatal anaemia caused by haemolytic disease of the foetus and newborn. Foetal antigens, which are normally expressed on platelets from the 16th week of pregnancy, may cause maternal immunisation, so that foetal and placental transfer of IgG antibodies may lead to neonatal thrombocytopenia. It has been reported an increase in the fetal platelet count after maternal treatment with prednisone (10 mg/daily) from 23 weeks gestation<sup>[102]</sup>. Alloimmune thrombocytopenia is cured today by intravenous immune globulin administered by 24 weeks gestation to pregnant women at risk due to a previously affected infant. Immunoglobulin 1 g/kg weekly with or without oral dexamethasone was first reported to lower the incidence of foetal cerebral hemorrhage, increasing platelet count, compared to untreated patients.

Dexamethasone 3-5 mg/d augments the effect of immune globulin, although, in some patients, it was associated with oligohydramnios and foetal growth restriction. Prednisone can also be used to treat fetuses with an inadequate response to immune globulin alone, but presumably because of its lower anti-inflammatory action a dose of 60 mg/daily is required. Overall, weekly immune globulin 1 g/kg starting at 24 weeks' gestation is the mainstay of therapy, while adjunctive corticosteroids is suggested in women who have failed prior treatments<sup>[103]</sup>.

### *Recurrent Pregnancy Loss*

As to maternal conditions that benefit from cortisone therapy, in addition to chronic inflammatory diseases with autoimmune character, a significant improvement of knowledge came from studies on the role of uterine natural killer cell (uNK) cytotoxicity in recurrent miscarriage. In early pregnancy there is an increase of uNK cells under the influence of steroids. They are believed to promote trophoblast growth and immune modulation at the foetal-maternal interface. Nevertheless, despite their presumptive physiological role, uterine and peripheral NK are involved in recurrent miscarriage and pregnancy loss, and their toxicity participates in the rejection of the product of conception<sup>[104]</sup>. GC are able to suppress in vitro NK and other inflammatory cells cytolytic activity and their tumor necrosis factor- $\alpha$  production<sup>[105]</sup>. It is worth to analyze the case of a patient with history of 19 consecutive miscarriages, in whom an high number of uNK had been found. She was first observed following 14 miscarriages between the 8th and the 10th gestational week. The remote medical history and the following investigation screen were negative: hormone profile, viral screen (toxoplasmosis, cytomegalovirus, hepatitis and herpes simplex virus), autoimmune screen (anti-DNA, mitochondrial and thyroid antibodies), full blood count, random blood sugar, karyotype analysis of both parents, ultrasound scan of the uterus, hysteroscopy, antiphospholipid syndrome screen including IgG and IgM anticardiolipin antibody titres and dilute Russell viper venom time, Leiden factor V gene mutation, prothrombin gene mutation, methyltetrahydrofolate reductase mutation, antithrombin III deficiency, and activated protein C resistance. The mid-luteal level of uNK was the highest the Author had ever recorded. Pre-conceptual prednisolone 5 mg/daily was prescribed, leading to five further early losses. Therefore, a dose of 20 mg/ daily preconceptual prednisolone was prescribed for 6 months prior to

conception. The hormone administration was stopped at the 5th week of her twentieth gestation. The pregnancy was complicated by foetal growth restriction and oligohydramnios. A caesarean section was performed at 33 weeks, with the birth of a 1484 g female in good conditions<sup>[106]</sup>. This was an unexplained result in the opinion of the Authors, although it is largely justified by the intensive regulatory action of the glucocorticoids on cellular and humoral immunity. In the absence of other maternal causes of miscarriage, the above mentioned foetal inability to turn off maternal gestational inflammation may be considered a possible cause of the recurrent miscarriages in this patient. Moreover, the foetal growth restriction shows that, despite the high dose administered, the hormone was not able to completely remove the utero-placental vascular compromise produced by gestational inflammation. It has been suggested that estrogens and GCs could act directly on uNK cells through their receptors, influencing gene transcription at the decidual level. In addition, they down regulate inflammatory cytokine production by a variety of other cells<sup>[107]</sup>. Although immunoglobulins are reported to be almost equally effective as prednisolone in suppressing in vitro NK cell cytolytic activity, it must be recalled that GC immuno-modulation is the result of a specific and complex action involving different cellular types and a large number of cytokines and prostanoids.

A combination of prednisone, aspirin, folate, and progesterone has been reported to be associated with a higher live birth rate and a better foetal outcome compared with no treatment<sup>[108]</sup>. On the other hand, it has been also reported that elevated plasma cortisol concentration in early pregnancy may predict subsequent risk of pre-term labour with apparent mediatory role for increased placental CRH output<sup>[109]</sup>. Nevertheless, the eventual clinical relevance of this finding remains to be established. However, NK percentage and cytotoxicity is not the only feature of gestational inflammation, since Th1/Th2 ratio imbalance is enough to trigger it. It follows that the measurement of this ratio in the maternal and foetal compartment is essential for the early diagnosis of potentially fatal complications.

Low-dose betamethasone alone throughout pregnancy for prevention of gestational early and late inflammatory complications has been reported in patients with history of recurrent miscarriage<sup>[110][111][112]</sup>. According to the Authors, this therapy, named 'Irpinia Resolution', showed a greater efficacy in

terms of live birth rate and neonatal well-being compared to other treatments. The patients in their clinical studies, due to history of 2 to 10 previous miscarriages or pregnancy loss, had been already studied with laboratory tests and operative hysteroscopies for the search of endometrial inflammatory cells, and treated with surgical excision of uterine fibroids or endometriosis foci. In addition, they had been cured with variable doses of single or combined drugs, including progesterone, aspirin, heparin and prednisolone. Therefore, they were assigned to low-dose betamethasone therapy without further investigation and regardless of the results of previous tests. In the opinion of the Authors, there are three main reasons for the better performance of low-dose betamethasone (usually 0,5 mg/daily until delivery): first, the well known greater anti-inflammatory activity of fluorinated GC compared to prednisolone; second, their resistance to inactivation by 11-beta-hydroxysteroid-dehydrogenase; third, their broad action against all aspects of the complex process of cellular and humoral inflammation. Thanks to these characteristics, betamethasone exerts its action precisely where it is required, that is at the level of the chorionic villi and maternal decidua, where gestational inflammation is triggered and produces its first effects.

Based on these evidences, these Authors encourage clinicians to adopt the 'Irpina Resolution' for prevention of gestational inflammation in single cases, without fear of foetal and maternal adverse events. Once the potential of this therapy has been sufficiently confirmed in selected cases, further validation by means of case-control trials comparing treated with non treated patients would be welcome before directing it to the general population.

## Concluding remarks

Uncontrolled Gestational Inflammation is the cause of the major obstetric complications, including euploid and aneuploid sporadic and recurrent miscarriage, foetal growth restriction, premature birth, up to perinatal and maternal death.

Recognize that major obstetric complications are due to the failure of the foetus to control gestational inflammation, is not a common mental attitude among clinicians. It is the Author's opinion that a greater diagnostic effort on the foetal causes, and more effective anti-inflammatory steroid therapy, would significantly improve live birth rate and perinatal well-being, meeting the expectations of the

women who suffer from the recurrent denial of their motherhood.

## References

1. <sup>△</sup>Jones RL, Stoikos C, Findlay JK, Salamonsen LA. *TG F-beta superfamily expression and actions in the endometrium and placenta. Reproduction.* 2006; 132: 2 17–232.
2. <sup>△</sup>Biondi C, Pavan B, Dalpiaz A, Valerio A, Spisani S, Vesce F. *Evidence for the presence of N-formyl-methionyl-leucyl-phenylalanine (fMLP) receptor ligands in human amniotic fluid and fMLP receptor modulation by physiological labour. J Reprod Immunol.* 2005; 68:71–83.
3. <sup>△</sup>Biondi C, Pavan B, Ferretti ME, Corradini FG, Neri L M, Vesce F. *Formyl-methionyl-leucyl-phenylalanine induces prostaglandin E2 release from human amnion-derived WISH cells by phospholipase C-mediated [Ca<sup>2+</sup>]<sub>i</sub> rise. Biol Reprod.* 2001; 64:865–70.
4. <sup>△</sup>Buzzi M, Vesce F, Ferretti ME, Fabbri E, Biondi C. *Does formyl-methionyl-leucyl-phenylalanine exert a physiological role in labor in women? Biol Reprod.* 1999; 60:1211–6.
5. <sup>a, b, c</sup>Lunghi L, Ferretti ME, Medici S, Biondi C, Vesce F. *Control of human trophoblast function. Reprod Biol Endocrinol.* 2007 Feb 8; 5:6.
6. <sup>△</sup>Labour: a delayed menstruation? Bjorn Gustavii. *Lancet.* vol 300, issue 778, 1149–1150 Nov 25, 1972. doi: 10.1016/s0140-6736(72)92759-6
7. <sup>△</sup>N Arbour, P Tremblay, D Oth N. *formyl – methionyl – leucyl – phenylalanine induces and modulates IL-1 and IL-6 in human PBMC. Cytokine.* 1996 Jun; 8 (6):468–75. doi:10.1006/cyto.1996.0063
8. <sup>△</sup>Harold Fox 'Pathology of the Placenta' (ISBN 13:9780702021961).
9. <sup>△</sup>Mertz D, Geraci J, Winkup J, Gessner BD, Ortiz JR, Lobe M. *Pregnancy as a risk factor for severe outcomes from influenza virus infection: a systematic review and meta-analysis of observational studies. Vaccine.* 2017; 35:521–8.
10. <sup>△</sup>Cornish EF, Filipovic I, Asenius F, Williams DJ, McDonnell T. *Innate Immune Responses to Acute Viral Infection During Pregnancy. Front Immunol.* 2020; 11: 572567.
11. <sup>△</sup>Fortunato Vesce, Chiara Battisti, Michele Crudo. *The Inflammatory Cytokine Imbalance for Miscarriage, Pregnancy Loss and COVID-19 Pneumonia. Front Immunol.* 11 March 2022; 13 – 2022. doi:10.3389/fimmu.2022.861245

12. <sup>△</sup>Wilczynski JR. Th1/Th2 cytokines balance – yin and yang of reproductive immunology. *Eur J Obstet Gynecol Reprod Biol.* 2005; 122: 136–143.
13. <sup>△</sup>Belardelli F. Role of interferons and other cytokines in the regulation of the immune response. *Apmis Journal of Pathology, microbiology and Immunology.* 1995; 103: 161–179.
14. <sup>△</sup>Darmochwal-Kolarz D, Leszczynska-Gorzela B, Rolinski J, Oleszczuk J. T helper 1- and t helper 2-type cytokine imbalance in pregnant women with pre-eclampsia. *Eur J Obstet Gynecol Reprod Biol.* 1999; 86: 165–170.
15. <sup>△</sup>Saito S, Sakai M. Th1/Th2 balance in preeclampsia. *J Reprod Immunol.* 2003; 59: 161–173. doi:10.1016/S0165-0378(03)00045-7
16. <sup>△</sup>Kharfi A, Giguère Y, Sapin V, Massé J, Dastugue B, Forest JC. Trophoblastic remodeling in normal and preeclamptic pregnancies: implication of cytokines. *Clin Biochem.* 2003; 36: 323–331. doi:10.1016/S0009-9120(03)00060-2
17. <sup>△</sup>Yoneyama Y, Suzuki S, Sawa R, Yoneyama K, Power GG, Arami T. Relation between adenosine and T-helper 1/T-helper 2 imbalance in women with preeclampsia. *Obstet Gynaecol.* 2002; 99: 641–646. doi:10.1016/S0029-7844(02)01657-5
18. <sup>△</sup>Koga K, Osuga Y, Yoshino O, Hirota Y, Ruimeng X, Hirata T, Takeda S, Yano T, Tsutsumi O, Taketani Y. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. *J Clin Endocrinol Metab.* 2003; 88: 2348–2351. doi:10.1210/jc.2002-021942
19. <sup>△</sup>Lala PK, Chakraborty C. Factors regulating trophoblast migration and invasiveness: possible derangements contributing to pre-eclampsia and fetal injury. *Placenta.* 2003; 24: 575–587. doi:10.1016/S0143-4004(03)00063-8
20. <sup>△</sup>Aziz Aris, Frédéric Lambert, Paul Bessette, Jean-Marie Moutquin. Maternal circulating interferon- $\gamma$  and interleukin-6 as biomarkers of Th1/Th2 immune status throughout pregnancy. *The Journal of Obstetrics and Gynaecology Research.* 01 November 2007. doi:10.1111/j.1447-0756.2007.00676.x
21. <sup>△</sup>I Caniggia, J Winter, S J Lye, M Post. Oxygen and placental development during the first trimester: implications for the pathophysiology of pre-eclampsia. *Placenta.* 2000 Mar-Apr;21 Suppl A:S25–30. doi:10.1053/plac.1999
22. <sup>△</sup>I Caniggia, J L Winter. Adriana and Luisa Castellucci Award lecture 2001. Hypoxia inducible factor-1: oxygen regulation of trophoblast differentiation in normal and pre-eclamptic pregnancies – a review. *Placenta.* 2002 Apr;23 Suppl A:S47–57. doi:10.1053/plac.2002.0815
23. <sup>△</sup>Caniggia I, Grisaru-Gravnosky S, Kuliszewsky M, Post M, Lye SJ. Inhibition of TGF- $\beta$  3 restores the invasive capability of extravillous trophoblasts in pre-eclamptic pregnancies. *J Clin Invest.* 1999; 103: 1641–1650.
24. <sup>△</sup>IM. Jogee, L. Myatt, P. Moore, M.G. Elder. Prostacyclin production by human placental cells in short-term culture. *Placenta.* Volume 4, Issue 3, July–September 1983, Pages 219–229. doi:10.1016/S0143-4004(83)80001-0
25. <sup>△</sup>Flood K, Peace A, Kent E, Tedesco T, Dicker P, Geary M, Malone FD, Kenny D. Platelet reactivity and pregnancy loss. *Am J Obstet Gynecol.* 2010 Sep;203(3):281.e1–5. doi:10.1016/j.ajog.2010.06.023. Epub 2010 Aug 3. PMID: 20684942
26. <sup>△</sup>M. Tulppala MD, Prof O. Ylikorkala MD, L. Viinikka MD. Thromboxane dominance and prostacyclin deficiency in habitual abortion. *The Lancet.* Volume 337, Issue 8746, 13 April 1991, Pages 879–881. doi:10.1016/0140-6736(91)90205-4
27. <sup>△</sup>Mark Anthony Dempsey, Karen Flood, Naomi Burke, Aoife Murray, Brian Cotter, Sieglinde Mullers, Patrick Dicker, Patricia Fletcher, Michael Geary, Dermot Kenny, Fergal D Malone. Platelet function in patients with a history of unexplained recurrent miscarriage who subsequently miscarry again. *Eur J Obstet Gynecol Reprod Biol.* 2015 May;188:61–5. doi:10.1016/j.ejogrb.2015.02.003. Epub 2015 Feb 26.
28. <sup>△</sup>Mazzoni E, Di Stefano M, Fiore JR, Destro F, Manfrini M, Rotondo JC, Casali MV, Vesce F, Greco P, Scutiro G, Martini F, Tognon MG. Serum IgG Antibodies from Pregnant Women Reacting to Mimotopes of Simian Virus 40 Large T Antigen, the Viral Oncoprotein. *Front Immunol.* 2017 Apr 10;8:411. doi:10.3389/fimmu.2017.00411. eCollection 2017.
29. <sup>△</sup>Elisa Mazzoni, Elena Pellegrinelli, Chiara Mazziotta, Carmen Lanzillotti, John Charles Rotondo, Ilaria Bononi, Maria Rosa Iaquina, Marco Manfrini, Fortunato Vesce, Mauro Tognon, Fernanda Martini. Mother-to-child transmission of oncogenic polyomaviruses BKPyV, JCPyV and SV40. *J Infect.* 2020 May;80(5):563–570. doi:10.1016/j.jinf.2020.02.006. Epub 2020 Feb 22.
30. <sup>△</sup>Tognon M, Tagliapietra A, Magagnoli F, Mazziotta C, Oton-Gonzales L, Lanzillotti C, Vesce F, Contini C, Rotondo J C, Martini F. Investigation on spontaneous abortion and Papilloma Virus infection. *Vaccines.* 2020;8(3):47.

31. <sup>△</sup>Contini C, Rotondo JC, Magagnoli F, Maritati M, Seraceni S, Graziano A, Poggi A, Capucci C, Vesce F, Tognon M, Martini F. Investigation on silent bacterial infection in specimens from pregnant women affected by spontaneous miscarriage. *Journal of Cellular Physiology*. 2018; 234(1):100–107. doi:10.1002/jcp.26952.
32. <sup>△</sup>Romero R, Gomez R, Ghezzi F, Yoon BH, Mazor M, Edwin SS, Berry SM. A fetal systemic inflammatory response is followed by the spontaneous onset of preterm parturition. *Am J Obstet Gynecol*. 1998 Jul;179(1):186–93. Gomez R, Romero R, Ghezzi F, Yoon BH, Mazor M, Berry SM. The fetal inflammatory response syndrome. *Am J Obstet Gynecol*. 1998 Jul;179(1):194–202.
33. <sup>△</sup>Vesce F, Buzzi M, Ferretti ME, Pavan B, Bianciotto A, Jorizzo G, Biondi C. Inhibition of amniotic prostaglandin E release by ampicillin. *Am J Obstet Gynecol*. 1998 Apr;178(4):759–64.
34. <sup>△</sup>Vesce F, Pavan B, Lunghi L, Giovannini G, Scapoli C, Piffanelli A, Biondi C. Inhibition of amniotic interleukin-6 and prostaglandin E2 release by ampicillin. *Obstet Gynecol*. 2004 Jan;103(1):108–13.
35. <sup>△</sup>Vesce F, Pavan B, Buzzi M, Pareschi MC, Bianciotto A, Jorizzo G, Biondi C. Effect of different classes of antibiotics on amniotic prostaglandin E release. *Prostaglandins Other Lipid Mediat*. 1999 Jun;57(4):207–18.
36. <sup>△</sup>Merz WM, Fischer-Betz R, Hellwig K, Lamprecht G. Pregnancy and autoimmune disease. *Deutsch Arztebl Int*. 2022; 119(9): 145156. doi:10.3238/arztebl.m2021.0353.
37. <sup>△</sup>Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? *Immunol Today*. 1993; 14: 353–356.
38. <sup>△</sup>Raj Raghupathy, Majedah Al-Azemi, Fawaz Azizieh. Intrauterine growth restriction: cytokine profiles of trophoblast antigen-stimulated maternal lymphocytes. *Clin Dev Immunol*. 2012;2012:734865. doi:10.1155/2012/734865. Epub 2011 Oct 31.
39. <sup>a, b</sup>Raghupathy R. Th1-type immunity is incompatible with successful pregnancy. *Immunol Today*. 1997; 18: 478–482.
40. <sup>△</sup>Vesce F, Farina A, Jorizzo G, Tarabbia C, Calabrese O, Pelizzola D, Giovannini G, Piffanelli A. Raised level of amniotic endothelin in pregnancies with fetal aneuploidy. *Fetal Diagn Ther*. 1996 Mar-Apr;11(2):94–.
41. <sup>△</sup>Vesce F, Scapoli C, Giovannini G, Piffanelli A, Geurts-Moespot A, Sweep FC. Plasminogen activator system in serum and amniotic fluid of euploid and aneuploid pregnancies. *Obstet Gynecol*. 2001 Mar;97(3):404–8.
42. <sup>△</sup>Bromage SJ, Lang AK, Atkinson I, Searle RF. Abnormal TGFbeta levels in the amniotic fluid of Down syndrome pregnancies. *Am J Reprod Immunol*. 2000; 44: 205–210. doi:10.1111/j.8755-8920.2000.440403.x.
43. <sup>△</sup>Wright A, Zhou Y, Weier JF, Caceres E, Kapidzic M, Tabata T, Kahn M, Nash C, Fisher SJ. Trisomy 21 is associated with variable defects in cytotrophoblast differentiation along the invasive pathway. *Am J Med Genet*. 2004; 130: 354–364. doi:10.1002/ajmg.a.30254.
44. <sup>△</sup>Vesce F, Scapoli C, Giovannini G, Tralli L, Gotti G, Valerio A, Piffanelli A. Cytokine imbalance in pregnancies with fetal chromosomal abnormalities. *Hum Reprod*. 2002 Mar;17(3):803–8.
45. <sup>△</sup>Gessi S, Merighi S, Stefanelli A, Mirandola P, Bonfatti A, Fini S, Sensi A, Marci R, Varani K, Borea PA, Vesce F. Downregulation of A (1) and A (2B) adenosine receptors in human trisomy 21 mesenchymal cells from first-trimester chorionic villi. *Biochim Biophys Acta*. 2012 Nov;1822(11):1660–70.
46. <sup>△</sup>Qinlan Li, Shuting Chen, Xinyi Dong, Sen Fu, Tianyu Zhang, Weiwei Zheng, Yonghong Tian, Donghui Huang. The Progress of Research on Genetic Factors of Recurrent Pregnancy Loss. *Genetic Research*. 2023. doi:10.1155/2023/9164374.
47. <sup>△</sup>X Shi, X Xie, Y Jia, S Li. Maternal genetic polymorphisms and unexplained recurrent miscarriage: a systematic review and meta-analysis. *Clin Genet*. 2017; 91(2):265–284. doi:10.1111/cge.12910.
48. <sup>△</sup>Engel SA, Erichsen HC, Savitz DA, Thorp J, Chahock SJ, Olshan AF. Risk of spontaneous preterm birth is associated with common proinflammatory cytokine polymorphisms. *Epidemiology*. 2005; 16(4):469–77. doi:10.1097/01.ede000016439.09250.31.
49. <sup>△</sup>Daniela Holst, Yves Garnier. Preterm birth and inflammation-The role of genetic polymorphisms. *Eur J Obstet Gynecol Reprod Biol*. 2008 Nov;141(1):3–9. doi:10.1016/j.ejogrb.2008.07.020. Epub 2008 Sep 9.
50. <sup>△</sup>Anells MF, Hart PH, Mullighan CG, Heatley SL, Robinson JS, McDonald H. Polymorphisms in immunoregulatory genes and the risk of histologic chorioamnionitis in Caucoid women: a case control study. *BMJ Pregnancy Childbirth*. 2005; 5:4. doi:10.1186/1471-2993-5-4.
51. <sup>△</sup>Raghupathy R. Pregnancy: success and failure with in the Th1/Th2/Th3 paradigm. *Semin Immunol*. 2001 Aug;13(4):219–27. doi:10.1006/smim.2001.0316. PMID 11437629.

52. <sup>^</sup>Schindler AE (January 2004). "First trimester endocrinology: consequences for diagnosis and treatment of pregnancy failure". *Gynecological Endocrinology*. 18 (1): 51–57. doi:10.1080/09513590310001651795. PMID 15106366.
53. <sup>^</sup>Ulrich U, Pfeifer T, Lauritzen C (September 1994). "Rapid increase in lumbar spine bone density in osteopenic women by high-dose intramuscular estrogen-progestogen injections. A preliminary report". *Hormone and Metabolic Research*. 26 (9): 428–431. doi:10.1055/s-2007-1001723. PMID 7835827. S2CID 260169203.
54. <sup>^</sup>Ulrich U, Pfeifer T, Buck G, Keckstein J, Lauritzen C (1995). "High-dose estrogen-progestogen injections in gonadal dysgenesis, ovarian hypoplasia, and androgen insensitivity syndrome: Impact on bone density". *Adolescent and Pediatric Gynecology*. 8 (1): 20–23. doi:10.1016/S0932-8610(12)80156-3. ISSN 0932-8610.
55. <sup>^</sup>Göretzlehner G, Lauritzen C, Römer T, Rossmannith W (1 January 2012). *Hormontherapien bei gynäkologischen Erkrankungen. Praktische Hormontherapie in der Gynäkologie*. Walter de Gruyter. pp. 227–228. ISBN 978-3-11-024568-4.
56. <sup>^</sup>Topozada MK (1983). "Monthly Injectable Contraceptives". In Goldsmith A, Topozada M (eds.). *Long-Acting Contraception*. pp. 93–103. OCLC 35018604.
57. <sup>^</sup>Ghadeer AbdulHussain, Fawaz Azizieh, Ma'asoum ah Makhseed, Raj Raghupathy. *Effects of Progesterone, Dihydroprogesterone and Estrogen on the Production of Th1/Th2/Th17 Cytokines by Lymphocytes from Women with Recurrent Spontaneous Miscarriage*. *Reprod Immunol*. 2020 Aug;140: 103132. doi:10.1016/j.jri.2020.103132.
58. <sup>^</sup>Hassan Shehata, Abdullatif Elfituri, Stergios K. Doumouchtsis, Mudiaga Eseajeberuo Zini, Amanda Ali, Haider Jan, Ramesh Ganapathy, Hema Divakar, Moshe Hod. *FIGO Good Practice Recommendations on the use of progesterone in the management of recurrent first-trimester miscarriage*. *International Journal of Gynecology & Obstetrics*. 2023. doi:10.1002/ijgo.14717.
59. <sup>^</sup>Adam J Devall, Argyro Papadopoulou, Marcelina Podesek, David M Haas, Malcolm J Price, Arri Coomasamy, Ioannis D Gallos. *Progesterone for preventing miscarriage: a network meta-analysis*. *Cochrane Database Syst Rev*. 2021 Apr 19;4(4):CD013792. doi:10.1002/14651858.CD013792.pub2.
60. <sup>^</sup>McLindon LA, James G, Beckmann MM, et al. *Progesterone for women with threatened miscarriage (STOP trial): A placebo-controlled randomized clinical trial*. *Hum Reprod*. 2023;38(4):560–68. doi:10.1093/humrep/dead029.
61. <sup>^</sup>Ting-Jung Lai, Sen-Wen Teng, Cheng-Kun Chang, Chen-Yu Huang. *Progesterone in Pregnancy: Evidence-Based Strategies to Reduce Miscarriage and Enhance Assisted Reproductive Technology*. *Med Sci Monit*. 2024 Mar 8;30:e943400. doi:10.12659/MSM.943400.
62. <sup>^</sup>Adam J Devall, Argyro Papadopoulou, Marcelina Podesek, David M Haas, Malcolm J Price, Arri Coomasamy, Ioannis D Gallos. *Progesterone for preventing miscarriage: a network meta-analysis*. *Cochrane Database Syst Rev*. 2021 Apr 19;4(4):CD013792. doi:10.1002/14651858.CD013792.pub2.
63. <sup>^</sup>Arri Coomasamy, Helen Williams, Ewa Truchanowicz, Paul T Seed, Rachel Small, Siobhan Quenby, Pratima Gupta, Feroza Dawood, Yvonne E M Koot, Ruth Bender Atik, Kitty W M Bloemenkamp, Rebecca Brady, Annette L Briley, Rebecca Cavallaro, Ying C Cheong, Justin J Chu, Abey Eapen, Ayman Ewies, Annemieke Hoek, Eugenie M Kaaijk, Carolien A M Koks, Tin-Chiu Li, Marjory MacLean, Ben W Mol, Judith Moore, Jackie A Ross, Lisa Sharpe, Jane Stewart, Nirmala Vaithilingam, Roy G Farquharson, Mark D Kilby, Yacoub Khalaf, Mariette Goddijn, Lesley Regan, Rajendra Rai. *A Randomized Trial of Progesterone in Women with Recurrent Miscarriages*. *N Engl J Med*. 2015 Nov 26;373(22):2141–8. doi:10.1056/NEJMoa1504927.
64. <sup>^</sup>W Colin Duncan. *Did the NICE guideline for progesterone treatment of threatened miscarriage get it right?* *Reprod Fert*. 2022 Apr 7;3(2):C4–C6. doi:10.1530/RAF-21-0122.
65. <sup>^</sup>Conde-Agudelo A, Romero R. *Vaginal progesterone does not prevent recurrent preterm birth in women with a singleton gestation, a history of spontaneous preterm birth, and a midtrimester cervical length >25 mm*. *Am J Obstet Gynecol*. 2022;227:923–6. doi:10.1016/j.ajog.2022.07.054.
66. <sup>^</sup>U.S. Food and Drug Administration. *FDA Commissioner and Chief Scientist announce decision to withdraw approval of Makena*. FDA; 2023. Accessed April 6, 2023. Available at: <https://www.fda.gov/news-events/press-announcements/fda-commissioner-and-chief-scientist-announce-decision-withdraw-approval-makena>.
67. <sup>^</sup>Prediction and prevention of spontaneous preterm birth. *ACOG Practice Bulletin No. 234*. American College of Obstetricians and Gynecologists. *Obstet Gynecol*. 2021;138:e65–90. doi:10.1097/AOG.0000000000004479.

68. <sup>^</sup>Anne-Marie Aubin, Liam McAuliffe, Kimberley Williams, Ashad Issah, Rosanna Diacci, Jack E McAuliffe, Salma Sabdia, Jason Phung, Carol A Wang, Craig E Pennell. "Combined vaginal progesterone and cervical cerclage in the prevention of preterm birth: a systematic review and meta-analysis." *Am J Obstet Gynecol MFM*. 2023 Aug;5(8):101024. doi:10.1016/j.ajogmf.2023.101024. Epub 2023 May 20.
69. <sup>^</sup>Francesco D'Antonio, Vincenzo Berghella, Daniele Di Mascio, Gabriele Saccone, Filomena Sileo, Maria Elena Flacco, Anthony O Odibo, Marco Liberati, Lamberto Manzoli, Asma Khalil. "Role of progesterone, cerclage and pessary in preventing preterm birth in twin pregnancies: A systematic review and network meta-analysis." *Eur J Obstet Gynecol Reprod Biol*. 2021 Jun;261:166-177. doi:10.1016/j.ejogrb.2021.04.023. Epub 2021 Apr 24.
70. <sup>^</sup>Dennis W. Thomas, Paulo N. Rocha, Chandra Nataraj, Lisa A. Robinson, Robert F. Spurney, Beverly H. Koller, Thomas M. Coffman. "Proinflammatory Actions of Thromboxane Receptors to Enhance Cellular Immune Responses." *J Immunol*. 2003;171(12):6389-6395. doi:10.4049/jimmunol.171.12.6389.
71. <sup>^</sup>M Tulppala, M Marttunen, V Söderstrom-Anttila, T Foudila, K Ailus, T Palosuo, O Ylikorkala. "Low-dose aspirin in prevention of miscarriage in women with unexplained or autoimmune related recurrent miscarriage: effect on prostacyclin and thromboxane A2 production." *Hum Reprod*. 1997 Jul;12(7):1567-72. doi:10.1093/humrep/12.7.1567.
72. <sup>^</sup>S W Walsh. "Low-dose aspirin: treatment for the imbalance of increased thromboxane and decreased prostacyclin in preeclampsia." *Am J Perinatol*. 1989 Apr;6(2):124-32. doi:10.1055/s-2007-999562.
73. <sup>^</sup>American College of Obstetricians and Gynecologists. "Hypertension in pregnancy." Washington, DC: American College of Obstetricians and Gynecologists; 2013. Available at: <http://www.acog.org/Resources-And-Publications/Task-Force-and-Work-Group-Reports/Hypertension-in-Pregnancy>. Retrieved January 24, 2018.
74. <sup>^</sup>Paulien G de Jong, Stef Kaandorp, Marcello Di Nisi, Mariëtte Goddijn, Saskia Middeldorp. "Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia." *Cochrane Database Syst Rev*. 2014 Jul 4;2014(7):CD004734. doi:10.1002/14651858.CD004734.pub4.
75. <sup>^</sup>Halide Yuksel, Semra Kayatas, Aysen Telce Boza, Murat Api, A Aktug Ertekin, Cetin Cam. "Low molecular weight heparin use in unexplained recurrent miscarriage." *Pak J Med Sci*. 2014 Nov-Dec;30(6):1232-1237. doi:10.12669/pjms.306.5477.
76. <sup>^</sup>Hamulyák EN, Scheres LJJ, Marijnen MC, Goddijn M, Middeldorp S. "Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss." *Cochrane Database of Systematic Reviews*. 2020, Issue 5. Art. No.: CD012852. doi:10.1002/14651858.CD012852.pub2.
77. <sup>^</sup>Siobhan Quenby, Katie Booth, Louise Hiller, Arri Comarasamy, Paulien G de Jong, Eva N Hamulyák, Luk J Scheres, Thijs F van Haaps, Lauren Ewington, Shreeya Tewary, Mariëtte Goddijn, Saskia Middeldorp; ALIFE2 Block Writing Committee; ALIFE2 Investigators. "Heparin for women with recurrent miscarriage and inherited thrombophilia (ALIFE2): an international open-label, randomised controlled trial." *Lancet*. 2023 Jul 1;402(10395):54-61. doi:10.1016/S0140-6736(23)00693-1. Epub 2023 Jun 1.
78. <sup>^</sup>Drugs and pregnancy. Edited by D. F. Hawkins. Second Edition. ChurchillLivingstone 1987, pag 85; pag 219
79. <sup>^</sup>Anthony E Michael, Aris T Papageorghiou. "Potential significance of physiological and pharmacological glucocorticoids in early pregnancy." *Hum Reprod Update*. 2008 Sep-Oct;14(5):497-517. doi:10.1093/humupd/dmno21. Epub 2008 Jun 13.
80. <sup>^</sup>Fantuzzi G, Ghezzi P. "Glucocorticoids as cytokine inhibitors: role in neuroendocrine control and therapy of inflammatory disease." *Mediators Inflamm*. 1993;2(4):263-70. doi:10.1155/S0962935193000365.
81. <sup>^</sup>Gottschall PE, Koves K, Mizuno K, Tatsuno I, Arimura A. "Glucocorticoid upregulation on interleukin-1 receptor expression in a glioblastoma cell line." *Am J Physiol*. 1991 Sep;261(3Pt1):E362-8. doi:10.1152/ajpendo.1991.261:E362-E368.
82. <sup>^</sup>Chinenov Y, Rogatsky I. "Glucocorticoids and the innate immune system: crosstalk with the toll-like receptor signalling network." *Mol Cell Endocrinol*. 2007 Sep 15;275(1-2):30-42. doi:10.1016/j.mce.2007.04.014. Epub 2007 May 13.
83. <sup>^</sup>Broering R, Montag M, Jiang M, Lu M, Sowa JP, Kleinehr K, Gerken G, Schlaak JF. "Corticosteroids shift the Toll-Like receptor response pattern of primary isolated murine liver cells from an inflammatory to an anti-inflammatory state." *Int Immunol*. 2011 Sep;23(9):537-44. doi:10.1093/intimm/dxr048. Epub 2011 Jul 1.
84. <sup>^</sup>Christopher D. Clark, Donna A. Santillan, Mark K. Santillan. "Betamethasone reverses AVP-induced dysfunction in trophoblast cells." POSTER SESSION III | FRIDAY, FEBRUARY 4, 2022 • 10:30 AM - 12:00 PM



- Volume 226, Issue 1, Supplement S443-S444 January 2022.
85. <sup>△</sup>F Vesce, M C Pareschi, S Travagli, C Tarabbia, F Panzini, G Salvatorelli, A M Gulinati, E Grandi, C Biondi. "Betamethasone-induced lecithin release in vitro from the fetal membranes." *Gynecol Obstet Invest.* 1992;33(3):134-7. doi:10.1159/000294866.
  86. <sup>△</sup>Yong-Sung Choi, Chae-Young Kim, Hye Kyung Chang, Young Joo Lee, Sung-Hoon Chung. "Antenatal Betamethasone Induces Increased Surfactant Proteins and Decreased Foxm1 Expressions in Fetal Rabbit Pups." *Int J Med Sci.* 2021 Jul 25;18(15):3367-3372. doi:10.7150/ijms.62286.
  87. <sup>△</sup>E. Murphy, R.J. Fittock, P.K. Zarzycki, M.M. Delahunty, R. Smith, V.L. Clifton. "Metabolism of Synthetic Steroids by the Human Placenta." *Placenta.* Volume 28, Issue 1, January 2007, Pages 39-46. doi:10.1016/j.placenta.2005.12.010.
  88. <sup>△</sup>N Costedoat-Chalumeau, S Georgin-Lavialle, Z Amoura, J C Piette. "Anti-SSA/Ro and anti-SSB/La antibody-mediated congenital heart block." *Lupus.* 2005;14(9):660-4. doi:10.1191/0961203305lu21950a.
  89. <sup>△</sup>K Shinohara, S Miyagawa, T Fujita, T Aono, K Kidoguchi. "Neonatal lupus erythematosus: results of maternal corticosteroid therapy." *Obstet Gynecol.* 1999 Jun;93(6):952-7. doi:10.1016/s0029-7844(99)00006-x.
  90. <sup>△</sup>A J J T Rein, D Mevorach, Z Perles, S Gavri, M Nadjari, A Nir, U Elchalal. "Early diagnosis and treatment of atrioventricular block in the fetus exposed to maternal anti-SSA/Ro-SSB/La antibodies: a prospective, observational, fetal kinetocardiogram-based study." *Circulation.* 2009 Apr 14;119(14):1867-72. doi:10.1161/CIRCULATIONAHA.108.773143. Epub 2009 Mar 30.
  91. <sup>△</sup>a, <sup>△</sup>b Mevorach D, Elchalal U, Rein AJJT. Prevention of complete heart block in children of mothers with anti-SSA/Ro and anti-SSB/La autoantibodies: detection and treatment of first-degree atrioventricular block. *Curr Opin Rheumatol.* 2009 Sep;21(5):478-82. doi:10.1097/BOR.0bo13e32832ed817.
  92. <sup>△</sup>Hayashi T, Kaneko M, Kim KS, Eryu Y, Shindo T, Iso da T, Murashima A, Ito Y, Sago H. Outcome of prenatally diagnosed isolated congenital complete atrioventricular block treated with transplacental betamethasone or ritodrine therapy. *Pediatr Cardiol.* 2009 Jan;30(1):35-40. doi:10.1007/s00246-008-9273-5. Epub 2008 Jul 26.
  93. <sup>△</sup>Brucato A. Prevention of congenital heart block in children of SSA-positive mothers. *Rheumatology.* 2008 Jun;47(suppl\_3):iii35-iii37. doi:10.1093/rheumatology/ken153.
  94. <sup>△</sup>Wada YS, Hama I, Goto M, Ito Y, Murashima. Long-term physical and neurodevelopmental outcomes after antenatal betamethasone administration for congenital heart block prevention. *J Matern Fetal Neonatal Med.* 2022 Nov;35(21):4175-4178. doi:10.1080/14767058.2020.1849089. PMID 33207991.
  95. <sup>△</sup>Speiser PW, White PC. Congenital adrenal hyperplasia. *N Engl J Med.* 2003 Aug 21;349(8):776-88. doi:10.1056/NEJMra021561.
  96. <sup>△</sup>Nimkarn S, New MI. Steroid 11beta-hydroxylase deficiency congenital adrenal hyperplasia. *Trends Endocrinol Metab.* 2008 Apr;19(3):96-9. doi:10.1016/j.tem.2008.01.002. Epub 2008 Feb 21.
  97. <sup>△</sup>Carlson AD, Obeid JS, Kanellopoulou N, Wilson RC, New MI. Congenital adrenal hyperplasia: update on prenatal diagnosis and treatment. *J Steroid Biochem Mol Biol.* 1999 Apr-Jun;69(1-6):19-29. doi:10.1016/s0960-0760(99)00059-x.
  98. <sup>△</sup>New MI, Tong YK, Yuen T, Jiang P, Pina C, Chan KC A, Khattab A, Liao GJW, Yau M, Kim SM, Chiu RWK, Sun L, Zaidi M, Lo YMD. Noninvasive Prenatal Diagnosis of Congenital Adrenal Hyperplasia Using Cell-Free Fetal DNA in Maternal Plasma. *J Clin Endocrinol Metab.* 2014 Feb 28;99(6):E1022-E1030. doi:10.1210/jc.2014-1118.
  99. <sup>△</sup>Peranteau WH, Wilson RD, Liechty KW, Johnson M P, Bebbington MW, Hedrick HL, Flake AW, Adzick N S. Effect of maternal betamethasone administration on prenatal congenital cystic adenomatoid malformation growth and fetal survival. *Fetal Diagn Ther.* 2007;22(5):365-71. doi:10.1159/000103298. Epub 2007 Jun 5.
  100. <sup>△</sup>Leung WC, Ngai C, Lam TPW, Chan KL, Lao TT, Tang MHY. Unexpected intrauterine death following resolution of hydrops fetalis after betamethasone treatment in a fetus with a large cystic adenomatoid malformation of the lung. *Ultrasound Obstet Gynecol.* 2005 Jun;25(6):610-2. doi:10.1002/uog.1912.
  101. <sup>△</sup>Yamashita A, Hidaka N, Yamamoto R, Nakayama S, Sasahara J, Ishii K, Mitsuda N. In utero resolution of microcystic congenital cystic adenomatoid malformation after prenatal betamethasone therapy: A report of three cases and a literature review. *J Clin Ultrasound.* 2015 Sep;43(7):451-7. doi:10.1002/jcu.22214. Epub 2014 Jul 15.
  102. <sup>△</sup>Murphy MF, Bussel JB. Advances in the management of alloimmune thrombocytopenia. *Br J Haematol.* 2007 Feb;136(3):366-78. doi:10.1111/j.1365-2141.2006.06418.x.
  103. <sup>△</sup>Arnold DM, Smith JW, Kelton JG. Diagnosis and management of neonatal alloimmune thrombocytopenia.

- ia. *Transfus Med Rev.* 2008 Oct;22(4):255-67. doi:10.1016/j.tmr.2008.05.003.
104. <sup>Δ</sup>Dosiou C, Giudice LC. Natural killer cells in pregnancy and recurrent pregnancy loss: endocrine and immunologic perspectives. *Endocr Rev.* 2005 Feb;26(1):44-62. doi:10.1210/er.2003-0021.
105. <sup>Δ</sup>Xu B, Makris A, Thomson C, Hennessy A. Glucocorticoids inhibit placental cytokines from cultured normal and preeclamptic placental explants. *Placenta.* 2005;26:654-60.
106. <sup>Δ</sup>Quenby S, Farquharson R, Young M, Vince G. Successful pregnancy outcome following 19 consecutive miscarriages: case report. *Hum Reprod.* 2003 Dec;18(12):2562-4. doi:10.1093/humrep/deg502.
107. <sup>Δ</sup>Henderson TA, Saunders PTK, Moffett-King A, Grome NP, Critchley HOD. Steroid Receptor Expression in Uterine Natural Killer Cells. *The Journal of Clinical Endocrinology & Metabolism.* 2003 Jan;88(1):440-449. doi:10.1210/jc.2002-021174.
108. <sup>Δ</sup>Tempfer CB, Kurz C, Bentz EK, Unfried G, Walch K, Czizek U, Huber JC. A combination treatment of prednisone, aspirin, folate, and progesterone in women with idiopathic recurrent miscarriage: a matched-pair study. *Fertil Steril.* 2006 Jul;86(1):145-8. doi:10.1016/j.fertnstert.2005.12.035. Epub 2006 May 23.
109. <sup>Δ</sup>Sandman CA, Glynn L, Dunkel Schetter C, Wadhwa P, Garite T, Chicz-DeMet A, Hobel C. Elevated maternal cortisol early in pregnancy predicts third trimester levels of placental corticotropin releasing hormone (CRH): priming the placental clock. *Peptides.* 2006 Jun;27(6):1457-63. doi:10.1016/j.peptides.2005.10.002. Epub 2005 Nov 22.
110. <sup>Δ</sup>Lunghi L, Pavan B, Biondi C, Paolillo R, Valerio A, Vesce F, Patella A. Use of glucocorticoids in pregnancy. *Curr Pharm Des.* 2010;16(32):3616-37. doi:10.2174/138161210793797898.
111. <sup>Δ</sup>Vesce F, Giugliano E, Cagnazzo E, Bignardi S, Mossuto E, Servello T, Marci R. The role of glucocorticoids in pregnancy: four decades experience with use of betamethasone in the prevention of pregnancy loss. In "Glucocorticoids. New recognition of our familiar friend". Edited by Xiaoxiao Qian, INTECH, November 2012, Croatia, pag 407-48. doi:10.5772/50797.
112. <sup>Δ</sup>Vesce F, Giugliano E, Cagnazzo E, Mossuto E, Marci R. Low dose of betamethasone throughout the whole course of pregnancy and fetal growth: a clinical study. *Eur Rev Med Pharmacol Sci.* 2014;18(4):593-8.

## Declarations

**Funding:** No specific funding was received for this work.

**Potential competing interests:** No potential competing interests to declare.